Skip to content

EV / sales at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
2.8×+0.2×
IQVIA logo
IQVIAIQV
2.6×-0.3×
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
4.9×+0.7×
Septerna, Inc. logo
Septerna, Inc.SEPN
14.3×-59.7×
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
0.9×-0.4×
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
0.7×+0.2×

Other financials

Income statement

See full
Revenue$636.5M-2.3%
Gross profit$123.6M+6.1%
Operating income-$3.4M+99.3%
Net income-$23.6M+95.8%
EPS (diluted)-$0.25+96.0%

Balance sheet

See full
Cash & equivalents$147.5M+45.2%
Total debt$1.1B-13.1%
Total equity$525.9M-38.8%
Total assets$2.7B-14.0%

Cash flow

See full
Operating cash flow-$17.0M+86.3%
CapEx$8.0M+176%
Free cash flow-$25.0M+80.3%

Valuation

See full
Market cap$1.61B+29.3%

Profitability

See full
Gross margin18.9%-1.3pp
Operating margin-13.1%-4.1pp
Net margin-16.5%-5.0pp
FCF margin5.8%+1.7pp

Returns & leverage

See full
Return on equity-64.5%0.0pp
Debt / equity2.1×+0.6×
Current ratio0.9×0.0×

Where this comes from

Calculated from Fortrea Holdings Inc.’s reported figures.

Based on the most recent quarter.

The official record: Fortrea Holdings Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fortrea Holdings Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fortrea Holdings Inc.'s EV / sales?
Fortrea Holdings Inc. (FTRE) reported EV / sales of 0.7× in Q1 2026.
How has Fortrea Holdings Inc.'s EV / sales changed year-over-year?
Fortrea Holdings Inc.'s EV / sales decreased by 1.6% year-over-year, from 0.7× to 0.7×.
What is the long-term trend for Fortrea Holdings Inc.'s EV / sales?
Over 2 years (2023 to 2025), Fortrea Holdings Inc.'s EV / sales has grown at a -24.2% compound annual growth rate (CAGR), from 1.6× to 0.9×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.